Your browser doesn't support javascript.
loading
Novel Heterozygous Missense Variants in Diacylglycerol Kinase Epsilon and Complement Factor I: Potential Pathogenic Association With Atypical Hemolytic Uremic Syndrome.
Abughanimeh, Omar K; Baljevic, Muhamed; Nester, Alex.
Afiliação
  • Abughanimeh OK; Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, USA.
  • Baljevic M; Division of Hematology-Oncology, Department of Internal Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, USA.
  • Nester A; Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, USA.
Cureus ; 16(1): e52633, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38374836
ABSTRACT
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy (TMA), which copresents with microangiopathic hemolytic anemia, thrombocytopenia, and kidney injury. While typical HUS is normally preceded by infections such as Shiga-toxin-producing Escherichia coli, atypical HUS (aHUS) has a genetic component that leads to dysregulation of the alternative complement pathway. We report a case of a 69-year-old female who developed aHUS after undergoing an elective knee surgery. Genetic testing revealed novel mutations affecting diacylglycerol kinase epsilon (DGKE) protein and complement factor I (CFI) that were not reported before as pathogenic. The patient was treated with eculizumab, leading to the complete resolution of TMA with no lasting organ damage.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article